Talk:Prostacyclin
This is the talk page for discussing improvements to the Prostacyclin article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Prostacyclin.
|
Mode of action HTML entity
editAs of Thursday February 6, 2014 there is "near" HTML entity in the Mode of action table - &earr;
It's likely supposed to be an up or down but I do not know which.
Untitled
editI think there is a wrong structure for prostacyclin!
- What do you think it should be? The structure here seems to be in agreement with, e.g. [1] David.Throop 17:53, 2 January 2007 (UTC)
Please check the structure of prostacyclin, again. It's formula is C20H32O5, but there are 21 Carbon in the structure showed in this website. Is there something wrong? If the structure is correct, the formula should be wrong. I think the formula is correct.
- OK, you're right. I have put in a request for a corrected picture.David.Throop 16:46, 8 January 2007 (UTC)
Good job and thanks.
John Vane's photo
editI moved photo of Vane to his bio, where it seemed more appropriate. Eperotao (talk) 23:15, 25 July 2009 (UTC)
Sources for article content
editWould you kindly let me know where the content of this page comes from? I see the diagram was drawn by jdfwolff. This is not a source I can quote or talk about to others if I don't know how the diagram was conceived of in the first place. Thank you. 75.24.118.130 (talk) 18:25, 21 September 2009 (UTC)Scott Kozak75.24.118.130 (talk) 18:25, 21 September 2009 (UTC)
History - Last paragraph
editI think the Lucy Clapp paragraph ought to be removed on the basis that it has no bearing on the history of (discovery of) prostacyclin and it cherry-picks a (very minor) scientific fact about prostacyclin from a very large body of literature.
I noted that this identical paragraph is present on the Treprostinil wiki page as well. Thanks, -david —Preceding unsigned comment added by Das312 (talk • contribs) 17:36, 23 May 2011 (UTC)
- Agreed. I've deleted the para. Possible we could use " treprostinil activates PPARs, another mechanism that contributes to the anti-growth benefits of the prostacyclin class." somewhere in the article if we had a source. - Rod57 (talk) 03:31, 29 December 2015 (UTC)
"Effective" vasodilator
editWhat's the difference between "effective vasodilator" and "vasodilator"? Is it like angiotensin, and classified as a "potent vasodilator"? 129.180.1.214 (talk) 13:18, 7 April 2013 (UTC)
Members section and table
editShould we call this Variations and analogues ? and explain the Class column on the right ? - Rod57 (talk) 03:16, 29 December 2015 (UTC)
Check half-life
editHi,
The half-life of prostacyclin is stated here to be 42 seconds. However, many articles put it around 3 to 10 minutes (see Sinzinger & Weber, 1988; Polterauer, Sinzinger & Peskar, 1986, cited below). Also, the source quoted there [5] relates to the half-life of PGE1 and E0 (?). Maybe I'm just missing something and they are the same? It would be nice if OP could clear up the discrepancy.
Sinzinger, H. and Weber, G., 1988. Reduced biological half-life of plasma prostacyclin in pre-eclampsia. Archives of gynecology and obstetrics, 243(4), pp.187-190.
Polterauer, P., Sinzinger, H. and Peskar, B.A., 1986. Biological half-life of prostacyclin and 6-oxo-PGF1α levels in plasma of patients with colonic cancer. Prostaglandins, Leukotrienes and Medicine, 22(3), pp.249-258.
Thanks and best regards 95.148.60.110 (talk) 18:04, 11 April 2020 (UTC)